Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4726 | serology test Wiki | 0.71 |
| drug4716 | saliva sample Wiki | 0.71 |
| drug2473 | NG Biotech Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004630 | Emergencies NIH | 0.12 |
| D014777 | Virus Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection. It is estimated that the child could be asymptomatic or pauci-symptomatic carrier and thus be vector of the disease. For this reason, measures have been taken to close schools and contain populations in a large number of countries, including France. However, there are no data on the prevalence of COVID-19 in children.
Description: children admitted to pediatric emergencies for respiratory signs Children hospitalized as a result of travelling to pediatric emergency departments for respiratory signs Respiratory asymptomatic children admitted to pediatric emergencies
Measure: Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients Time: at the end an average 28 daysDescription: the degree of relationship with these contacts and the time spent in contact with them within 24 hours before emergency
Measure: Contact frequency Time: At inclusionThe purpose of this study is to provide weekly data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.
Description: serology
Measure: Seroconversion against SARS-CoV2 in children Time: at inclusionDescription: Serology, measure of Ab in children
Measure: Protective immunity Time: at inclusionDescription: Serology in children
Measure: Measure of Ab antiN and Ab anti-S1/2 Time: at inclusionDescription: Serology in children
Measure: Neutralization activity Time: at inclusionDescription: in children, qualitative and quantitative measure , in nasopharynx, saliva and stool
Measure: Positive qPCR in children Time: at inclusionDescription: in children, qualitative and quantitative measure , in nasopharynx, saliva and stool, Ab anti-N, Ab anti-S1/2, neutralization serum
Measure: correlation between different Ab and qPCR and neutralization activity Time: at inclusionDescription: Serology, measure of Ab in PCR positive children
Measure: Protective immunity Time: Day 7Description: Serology, measure of Ab in PCR positive children
Measure: Protective immunity Time: Day 15Description: Serology, measure of Ab in PCR positive children
Measure: Protective immunity Time: Day 30Description: Serology, measure of Ab in PCR positive children
Measure: Protective immunity Time: At 6 monthsDescription: Serology, measure of Ab in PCR positive children
Measure: Protective immunity Time: At 12 monthsDescription: Sars-Cov2 PCR in PCR positive children
Measure: duration of viral carriage in stool, saliva and or nasopharynx Time: until 30 days post onsetDescription: Serology in PCR positive children
Measure: correlation between antibody profile and viral clearance Time: until 30 days post onsetDescription: Immune cells in positive PCR children
Measure: Ab profile and memory of immunity Time: At Day 7Description: Immune cells in positive PCR children
Measure: Ab profile and memory of immunity Time: At Day 15Description: Immune cells in positive PCR children
Measure: Ab profile and memory of immunity Time: At Day 30Description: Immune cells in positive PCR children
Measure: Ab profile and memory of immunity Time: At 6 monthsDescription: Immune cells in positive PCR children
Measure: Ab profile and memory of immunity Time: At 12 monthsDescription: Serology and qPCR in positive PCR children
Measure: Transmission to other family members Time: Until 30 daysDescription: Clinical examination and questioning in positive PCR children
Measure: Presence of COVID-19 Symptom Time: Until 12 months of follow-upDescription: Ancillary study: Serology in parents
Measure: seroconversion against SARS-CoV2 in parents Time: at inclusionDescription: Ancillary study: Serology in parents
Measure: Measure of Ab antiN and Ab anti-S1 and neutralization activity Time: at inclusionDescription: Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva
Measure: Positive qPCR in parents Time: at inclusionDescription: Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva, Ab anti-N, Ab anti-S1, neutralization serum
Measure: correlation between different Ab and qPCR Time: at inclusionDescription: Ancillary study: Serology in PCR positive parents
Measure: correlation between antibody profile and viral clearance Time: until 30 days post onsetDescription: Ancillary study: Immune cells in positive PCR parents
Measure: Ab profile and memory of immunity Time: at Day 7Description: Ancillary study: Immune cells in positive PCR parents
Measure: Ab profile and memory of immunity Time: at Day 15Description: Ancillary study: Immune cells in positive PCR parents
Measure: Ab profile and memory of immunity Time: at Day 30Description: Ancillary study: Immune cells in positive PCR parents
Measure: Ab profile and memory of immunity Time: at 6 monthsDescription: Ancillary study: Immune cells in positive PCR parents
Measure: Ab profile and memory of immunity Time: at 12 monthsDescription: Serology and qPCR in positive PCR parents
Measure: Transmission to other family members Time: Until 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports